The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...

Although Novo was first to market with Wegovy and its sister ... The company is also studying Zepbound’s impact on illness and death in a trial that’s due to deliver results in 2027.

Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...

Novo shareholder, Markus Manns, portfolio manager at mutual funds firm Union Investment, said: “The guidance cut was widely ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Obesity drugmaker Novo Nordisk has today downgraded its 2025 sales forecast, ending a four-year stretch of steady guidance ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Major benchmarks are down this year amid concerns about import tariffs and their impact on economic growth. The stock market may not seem like the ... evaluating the safety and efficacy of Zepbound ...